HK innoN is is a pharmaceutical company which manufactures and sells prescription drugs, hangover remedies, health functional foods, and dermocosmetics. Key products in the prescription drug segment include K-CAB, Rovazet, and Akynzeo, with K-CAB being the 30th new drug in South Korea. Major products in the HB&B business segment are Condition, Hutgaesoo, and B-Wants. In the research and development field, the company focuses on innovative drug pipelines for cancer, liver diseases, and autoimmune diseases, aiming to discover the next 'K-CAB.'

Targeted Drug Delivery Systems: HK innoN has made significant strides in developing targeted drug delivery systems. These systems ensure that drugs reach their intended targets with greater precision, minimizing side effects and enhancing therapeutic efficacy. Biologics Development: The company has a strong focus on biologics, a class of drugs derived from living organisms. Their expertise in biologics development has led to the creation of innovative therapies for various diseases. Combinatorial Chemistry: HK innoN employs combinatorial chemistry to rapidly synthesize and screen large libraries of compounds. This approach accelerates the discovery of potential drug candidates and optimizes lead compounds. High-Throughput Screening: By utilizing high-throughput screening technologies, HK innoN can efficiently evaluate the biological activity of a vast number of compounds, expediting the drug discovery process. Computational Chemistry: Computational chemistry plays a crucial role in HK innoN's drug discovery efforts. It enables researchers to model and simulate molecular interactions, aiding in the design of novel drug candidates.

Private

Pharma, CDMO, Bio